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ABSTRACT 
The objective of this study was to evaluate the anticancer properties of L-asparaginase purified 
from fungal isolate Fusarium culmorum ASP-87 against human T-cell leukemia cell line 
(Jurkat). The growth inhibitory and proapoptotic effects of purified L-asparaginase on Jurkat cell 
lines were investigated by determining its influence on cell viability, colony formation, DNA 
fragmentation and cell cycle progression. The results revealed that purified L- asparaginase 
showed significant decrease in cell survival with IC50 value of 90µg/ml(9 IU/ml). The enzyme 
inhibited colony formation and showed characteristic laddering pattern on agarose gel thereby 
confirming the induction of apoptosis. Further, cell cycle analysis revealed that the enzyme 
induced apoptotic cell death by arresting the growth of cells at G2-M phase. However, the 
enzyme did not elicit any toxic effects on human erythrocytes. L-asparaginase purified from 
Fusarium culmorum ASP-87 showed significant and selective cytotoxic and apoptotic effects on 
human T-cell leukemic cells in dose dependent manner. Results of the study give leads for the 
anticancer effects of fungal L-asparaginase and its potential usefulness in the chemotherapy of 
leukemia. 
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INTRODUCTION 
Therapeutic enzymes are enzymes which can be used medically with other therapies for the 
treatment of various diseases. A variety of enzymes have therapeutic applications. A potential 
application of therapeutic enzymes is in the chemotherapy of cancer. L-asparaginase is an 
important therapeutic enzyme which causes the hydrolysis of L-asparagine to L-aspartic acid and 
ammonia. The most common therapeutic indications of L-asparaginase are in the treatment of 
Hodgkin’s disease, acute lymphocytic leukemia, acute myelocytic leukemia, acute 
myelomonocytic leukemia and chronic lymphocytic leukemia, lymphosarcoma and 
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melanosarcoma [1-7]. The clinical effect of asparaginase is related to depletion of serum 
asparagine, an amino acid required for the growth of leukemic cells. The administration of L-
asparaginase results in rapid and complete deamination of the amino acid (asparagine) in the 
plasma. Normal cells however are able to synthesize L-asparagine and are less affected by its 
rapid depletion. Asparagine depletion inhibits protein and RNA synthesis and also induces cell 
cycle arrest and apoptosis in leukemic cell lines [8,9].The bacterial strains such as Escherichia 
coli and Erwinia chrysanthemi are reported to produce L-asparaginase and have been extensively 
used for the treatment of ALL [10,11]. The use of L-asparaginase from bacterial origin has been 
reported to cause pancreatitis, liver dysfunction, neurological seizures that may guide to 
intracranial thrombosis or haemorrhage and hypersensitivity leading to allergic reactions and 
anaphylaxis [12-15]. In view of the fact that L-asparaginase from eukaryotic microorganisms is 
known to have less adverse effects [16] our laboratory was interested in evaluating the 
cytotoxicity of L-asparaginase purified from a fungus, Fusarium culmorum ASP-87 [17] by 
performing an array of invitro assays on human T-cell leukemic cell line (Jurkat). 
 
MATERIALS AND METHODS 
Chemicals 
RPMI 1640 culture medium, Dulbecco's Modified Eagle Medium (DMEM), RNase A, 
proteinase K were purchased from Sigma-Aldrich (St Louis, USA). Fetal bovine serum (FBS) 
phosphate-buffered saline (PBS) 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
(MTT), dimethyl sulfoxide (DMSO) and Propidium Iodide (PI) were purchased from Himedia 
(Mumbai, India). L-asparaginase used in the study was isolated from a tropical soil fungus 
Fusarium culmorum ASP-87.  
 
Production of L-asparaginase by Fusarium culmorum ASP-87 
The fungal culture was maintained on potato dextrose agar (PDA) slant at 4
°
C and sub cultured 
on PDA plates, incubated at 30
°
C for 6 days and used as inoculum. The culture medium used for 
the study was modified Czapek-dox medium containing g/l of, Glucose,2.0; L-asparagine,10.0; 
KH2PO4,1.52; KCL,0.52; MgSO4.7H2O,0.52; CuNO3.3H2O,trace; ZnSO4.7H20,trace; 
FeSO4.7H20,trace; pH 7.5 [18]. Modified Czapek-dox broth (200 ml) was prepared, sterilized 
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and inoculated with F. culmorum ASP-87 spore suspension (10
6
/ml). The cultures were 
incubated at 30
°
C under shaken condition (120 rpm) for 4 days. The crude L-asparaginase 
extracted from the fungus was partially purified by ammonium sulphate precipitation (salting 
out). A four day old culture filtrate (200ml) of F. culmorum ASP-87 grown in modified Czapek-
dox broth was collected after centrifugation at 8000 rpm for 10 min at 4
°
C. All subsequent 
purification steps were carried out at 4
°
C. The crude enzyme was subjected to ammonium sulfate 
precipitation and the protein precipitates were collected at 0 to 40 %, 40 to 70 % and 70 to 90% 
salt saturation. The precipitates at each saturation was collected by centrifugation at 10,000 rpm 
for 15min and resuspended in 0.01M Tris-HCl buffer (pH-7.2). The protein precipitates obtained 
after each saturation were tested for L-asparaginase activity and the precipitates showing 
maximum activity was dialyzed overnight against 0.01M Tris-HCl buffer [19].The precipitate 
was purified by size exclusion chromatography and ion exchange chromatography. It was further 
purified by SDS-PAGE by passive diffusion method [20] (Figure 1). The purified sample was 
run along with standard L-asparaginase (procured from sigma Cat no. 3809) in precoated TLC 
plates. The test compound appeared as a single spot in TLC plate and the test sample was found 
to possess the same Rf value (0.266/90 kDa). The purity of the extracted L-asparaginase was 
found to be approximately 98% [17]. 
 
Cell lines and cell culture 
The human T-cell leukemia cell line Jurkat was procured from ATTC (USA). The cells were 
grown in RPMI 1640 medium supplemented with 10% heat inactivated FBS and cultured at 37
º
C 
under 5% CO2 and 95% humidity. Cells were used in exponential growth throughout all the 
experiments. 
 
Cell viability assay 
One hundred microliter (100 µl) of Jurkat cells (1 × 10
4
 cells/well) in RPMI-1640 medium were 
seeded onto 96-well culture plate and incubated overnight at standard conditions. The cells were 
treated with different concentrations of L-asparaginase (1.56 to 100 µg/ml) and incubated for 24 
h. Cells treated with culture medium served as a negative control. The supernatant from each 
well was removed and the cells were treated with 20 μl of MTT solution (5 mg/mlin PBS) and 
incubated for 4h at 37
°
C in a CO2 incubator. The formazan crystals formed were solubilized by 
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adding 100µl of Di-methyl Sulphoxide (DMSO) and the plates were read at 570nm using a 
microplate reader [21]. All experiments were performed in quadruplicate, and the cell viability is 
expressed as the percent relative to control cells. 
 
Clonogenic assay 
Clonogenic assay is a test routinely performed in the laboratory to determine the effectiveness of 
cytotoxic agents [22]. Jurkat cells (5 × 10
3
 cells/dish) was plated on dishes containing RPMI 
complete media and incubated at standard conditions for 24 h. After 24 h, cells were treated with 
50 and 100 µg/ml of L-asparaginase for 24 h. Cells were grown for 21 days and fresh media is 
added on the seventh day. On the 21
st
 day the media was removed from the dishes and washed 
once with PBS (pH 7.2). Cells were fixed with 6 % glutaraldehyde for 5 min, followed by 
staining the colonies with 1 ml of 0.5% crystal violet in PBS for 30 minutes on a rocking 
platform. The dishes were rinsed three times with PBS and gently air-dried, and the colonies 
were counted manually. 
 
DNA fragmentation analysis 
DNA fragmentation assay is a qualitative method for assessing cell death by detecting DNA 
fragments using agarose gel electrophoresis.  Jurkat cells (5 × 10
5
/ml) were treated with L-
asparaginase at 50 µg/ml and 100 µg/ml concentrations and incubated at 37° C for 24 h. The 
cells were transferred into 1.5-ml sterile microcentrifuge tubes and centrifuged at 2000 rpm for 5 
minutes at 4°C and supernatant was discarded. The cell pellet was dissolved in 20 μl of TES lysis 
buffer. 10 μl of DNase-free RNase A was added to above mixture and incubated for 30 minutes 
at 37°C. 10 μl of proteinase K was added and incubated at 50°C for 90 minutes. 5 μl of DNA 
loading buffer was added and the DNA samples were loaded into wells of 1% agarose gel 
containing 0.5 µg/ml of ethidium bromide. DNA ladders were visualized under UV 
transilluminator and photographed [23]. 
 
Cell cycle analysis 
Cell cycle analysis was performed by flow cytometric analysis after staining Jurkat cells with 
propidium iodide. Jurkat cells (1 × 10
6
/ml) were cultured in a p35 culture dishes containing 1 ml 
of medium under standard conditions. After 24h, cells were treated with 50 µg and 100 µg/ml L-
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asparaginase and incubated for 18h. Wells containing Dimethyl sulfoxide (DMSO) suspended in 
Dulbecco's Modified Eagle Medium (DMEM) (1 ml/well) served as control.After incubation, the 
cells were harvested and washed twice with PBS, fixed in 70% ethanol overnight and stored at - 
20° C. The cells were resuspended in 20 µg/ml propidium iodide (PI) containing 20 µg/ml 
RNase A in PBS and incubated at 37° C for 30 min. The percentage of cells in various stages of 
cell cycle in L-asparaginase treated and un-treated populations were determined using 
Fluorescence Activated Cell Sorting (FACS) and analyzed by flow cytometry [24]. The results 
were expressed as percentage of the cells in each phase. 
 
Isolation of erythrocytes 
One to Five ml of blood was collected from healthy volunteers in the age group of 20 to 25 
following the Helsinki protocol. The blood samples were collected in tubes containing EDTA 
and centrifuged at 3000 rpm for 10 min at 4
°
C. The erythrocytes were washed three times with 
PBS, pH 7.2 for 5 min. Washed erythrocytes were stored at 4
°
C and used within 6 h for the 
haemolysis assay. 
 
Haemolysis assay 
Haemolytic assay was performed to investigate the effect of purified L-asparaginase on normal 
cells. The haemolysis experiments were carried out in erythrocyte suspension. The effect of 
enzyme was assessed by preincubating the erythrocyte suspensions with different concentrations 
of L-asparaginase (10 µg – 320 µg/ml) at 37° C for 60 min. 100 µl of PBS was used as negative 
control with 0 % haemolysis and 1% SDS was used as positive control with 98 % haemolysis. 
After incubation, the erythrocyte suspensions were centrifuged at 3000 rpm for 10 min. The 
percentage of haemolysis was measured in a UV-visible spectrophotometer by analyzing the 
concentration of hemoglobin released into supernatant at 540 nm. The haemolysis results were 
presented as the percentage of complete haemolysis [25]. 
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Statistical analysis 
All the experiments were carried out in triplicates and statistical analysis was performed using 
SPSS software (version 20). Values were expressed as mean ±SD. The statistical difference 
between mean values were assessed by student t test at a significance level of (p<0.05) and 
comparisons were made between the control and the other groups. 
 
RESULTS  
Cell viability assay 
The MTT (3-(4,5-dimethylthiazol-2-yl)2,5-diphenyl tetrazolium bromide) assay is a reliable 
method to analyze the growth inhibitory properties of test compounds. It is a non radioactive, 
fast and economical assay widely used to quantify cell viability and proliferation. Hence in the 
current study effect of different concentrations of L-asparaginase (1.56 µg – 100 µg/ml) on the 
growth and viability of Jurkat cells was assessed by MTT assay. The results revealed that L-
asparaginase decreased the cell viability of Jurkat cells in a dose dependent manner with an 
IC50value of 90µg/ml is equal to 9 IU/ml. The results are shown in (Figure 2). This gives an 
indication about the inhibitory effect of L-asparaginase on the growth and proliferation of Jurkat 
cells, thereby indicating its antileukemic activity. 
 
Clonogenic assay 
The clonogenic cell survival assay determines the ability of a cell to proliferate indefinitely, 
thereby retaining its reproductive ability to form a large colony. We investigated the effect of L-
asparaginase on clonogenic survival of Jurkat cells. The cells treated with L-asparaginase, 
showed a lower survival rate of Jurkat cells which was found to be dose dependent. The cells 
treated with lower dose of L-asparaginase (50µg/ml) showed moderate inhibition on colony 
formation. However, higher concentration (100µg/ml) showed appreciable inhibition on colony 
(Figure 3a and b). 
DNA fragmentation analysis 
Apoptosis is an organized process that signals the cell to self destruct for renewal or to control 
aberrant cell growth. In order to delineate the mechanism of cell death mediated by L-
asparaginase, DNA fragmentation assay was performed. One of the hallmark features of 
apoptosis is the cleavage of genomic DNA into oligonucleosomal fragments in the form of 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
ladder. Jurkat cells treated with different concentrations of L-asparaginase (50 and 100 µg/ml) 
showed dose dependent characteristic laddering pattern on agarose gel thereby conforming the 
induction of apoptosis, but there was no ladder formation observed in control cells (Figure 4). 
 
Cell cycle analysis 
The cell cycle is a recurring sequence of events that includes the duplication of cell contents and 
its subsequent division. The effect of L-asparaginase on cell cycle progression was evaluated by 
flow cytometry. The results revealed that Jurkat cells treated with L-asparaginase exhibited cell 
cycle arrest at G2-M phase. The cell cycle changes were confirmed by significant increase in the 
accumulation of cells in G2-M phase and a marked decrease in the number of cells in G0-G1 
phase (Figure5). It was observed that when treated with L-asparaginase at a concentration of 50 
µg/ml and 100 µg/ml the cells in G2-M phase exhibited a population of 12.57 % and 19.78 % 
respectively as against 9.07 % in the untreated control. Interestingly, this was concomitant with a 
significant decrease in the cell population in G0-G1 phase (75.39 % at 50 µg/ml and 64.19 % at 
100 µg/ml concentration of L-asparaginase as against 81.76 % in the control). No significant 
changes were observed in the population of cells in the S phase in the L-asparaginase treated 
groups as compared to control (Figure6). This suggests that treatment with L-asparaginase 
arrested the cells in G2-M phase thereby preventing them from entering into subsequent phases 
of the cell cycle. The results of flow cytometry analysis confirmed the induction of apoptosis and 
cell cycle arrest at G2-M phase. 
 
Haemolysis assay 
Hemolysis refers to the damage of red blood cells leading to the release of intracellular 
erythrocyte content into blood plasma. In vitro hemolytic activity of L-asparaginase purified 
from Fusarium culmorum was studied on human erythrocytes at different concentrations ranging 
from (10µg – 320µg/ml). It was observed that purified L-asparaginase was nontoxic to 
erythrocytes even at higher concentrations (320µg/ml).  The results are shown in (Figure 7).  
This indicates that L-asparaginase do not posses any toxic effects on normal cells. 
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DISCUSSION 
Leukemia, the cancer of white blood cells is the most common malignancy in children and 
adolescents. L-asparaginase an enzyme which catalyzes the hydrolysis of amino acid L-
asparagine to L-aspartic acid and ammonia, has been widely used in the treatment of leukemia. 
The current study reveals the growth inhibitory and antiproliferative effects of L-asparaginase 
from F. culmorum ASP-87 on human T-cell leukemia cell line (Jurkat). The cytotoxicity of 
purified L-asparaginase was tested against human leukemic cell lines and found decrease in the 
cell viability of Jurkat cells in a dose dependent manner. Several reports earlier suggest the in 
vitro cytotoxicity of purified L-asparaginase against different cell lines such as human myeloid 
leukemia HL-60 [26], human breast cancer MCF-7 and human myelogenous leukemia K-562 
[27], human colon cancer CACO-2 and human cancer prostrate PC-3 [28], gastric cancer (AGS) 
[29], Hepato cellular carcinoma (Hep-G2) [30] and human gastric cancer cell line (MKN-28) and 
human T lymphoblastic leukemia cell line (MOLT-4) [31]. L-asparaginase purified from 
Penicillium brevicompactum NRC 829 and Aspergillus flavus (KUFS20) was cytotoxic to 
hepatocellular carcinoma (Hep-G2) and human breast cancer cells (MCF-7) with IC50 value of 
43.3µg/ml and 120.87µg/ml respectively [30, 32]. However, commercially available L-
asparaginase from E. coli and Erwiniacarotovora have been reported to have IC50 value of 1.0 
IU/ml and 7.5 IU/ml respectively on the similar cell lines [33]. The results of clonogenic assay 
were in line with the results obtained by MTT assay. The DNA fragmentation results were in 
concordance with earlier reports by Story et al. which showed characteristic fragmentation of 
DNA of mouse lymphoma cell line (LY-TH) after L-asparaginase treatment indicating apoptosis 
as the mode of cell death [34]. L-asparaginase purified from Enterobacter cloacae also showed 
characteristic laddering pattern of DNA of human myeloid leukemia HL-60 cell line [26]. The 
fragmentation of DNA may be due to the activation of caspase 3 which inactivates DFF-45 
(DNA fragmentation factor) and ICDA (Inhibitor of caspase-activated DNase) which in turn 
release active DFF-40 or CAD (Caspase activated DNase) [35, 36].  
 
Induction of apoptotic death may be due to elevation of some cell cycle inhibitors that have been 
reported to suppress cell cycle progression, resulting in G2-M phase arrest in P388 leukemia cells 
[37]. However, earlier reports by Shimizu et al. and Ueno et al. suggested that L-asparaginase 
purified from bacterial source Escherichia coli induced apoptosis of leukemia cells in association 
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with cell cycle arrest at G1 phase [38, 39]. But, on the contrary Pagliardi et al. reported that L-
asparaginase induced apoptosis of lymphoblastic leukemia cells with cell cycle arrest at S phase 
[40]. The cell cycle is regulated by activation of a family of cyclin dependent kinases (CDKs) 
and cyclins [41, 42]. King et al. reported that the G2-M phase transition was regulated by cyclin 
A and cyclin B [43].It is possible that the purified L-asparaginase would have exerted 
modulatory activity on cyclin A and cyclin B which plays a key role in regulating G2-M phase 
transition. The major setback with cancer chemotherapy is the absence of selective cytotoxic 
effects leading to cytotoxic effects on all (normal and cancerous) actively proliferating cells. This 
frequently results in dreadful side effects in patients including a drastic drop in cell counts (WBC 
and RBC) and severe anemic conditions. Although erythrocytes are not good models for normal 
cells, to understand whether asparaginase is haemocompatible, haemolysis assay was performed 
on erythrocytes [44].The in vitro haemolysis assay results were in concordance with earlier 
reports of Husain et al. and Mahajan et al. which showed L-asparaginase purified from 
Enterobacter cloacae and Bacillus licheniformis RAM-8 was not toxic to human erythrocytes at 
higher concentrations [26, 27]. This result may suggest that L-asparaginase may exert selective 
cytotoxicity only on leukemic cells, making it an ideal candidate for cancer chemotherapy 
especially for leukemia. 
 
CONCLUSION 
The current study reveals the growth inhibitory and antiproliferative effects of L-asparaginase 
from F. culmorum ASP-87 on human T-cell leukemia cell line (Jurkat). The observed cytotoxic 
effect of L-asparaginase on Jurkat cells is due to the induction of cell cycle arrest and apoptosis. 
The enzyme was found to be selectively cytotoxic to cancer cells with no observed adverse 
effects on erythrocytes suggesting that the enzyme was much haemocompatible for drug delivery 
applications and hence could be considered as a potential candidate for further pharmaceutical 
applications as an anticancer drug. 
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FIGURE LEGENDS 
Figure 1 SDS-PAGE analysis of purified L-asparaginase from F. culmorum ASP- 87. M =  
Protein molecular weight marker. Lane 1 = Crude preparation. Lane 2 = Ammonium sulfate 
precipitated fraction. Lane 3 = Ion exchange fraction (Purified protein). 
 
Figure 2Effect of L-asparaginase on the viability of Jurkat cells; the cells were treated with or 
without L-asparaginase (1.56 -100 µg/ml) and cell viability was determined by MTT assay.  
Values were expressed as mean ± SD. (*P< 0.05, **P< 0.01) represents the statistical 
significance between control and L-asparaginase treated cells by student’s t-test. 
 
Figure 3Effect of L-asparaginase on colony formation in Jurkat cells. (a)L-asparaginase 
treatment shows suppression of colony formation. (b) Graphical representation of number of 
colonies.Values were expressed as mean ± SD. (*P<0.05) represents the statistical significance 
between control and L-asparaginase treated cells by student’s t-test. 
 
Figure 4Detection of apoptosis by DNA fragmentation assay in Jurkat cells treated with L-
asparaginase from F. culmorum ASP-87. Agarose gel electrophoresis of DNA extracted from 
Jurkat cells. Lane 1 and 3 represents L-asparaginase treated cells (50 and 100 µg/ml) showing 
oligonucleosomal DNA fragments. Lane 2 and 4 represents untreated control cells.  Lane M is 
DNA molecular weight marker. 
 
Figure 5Effect of L-asparaginase on the cell cycle progression in Jurkat cells. The percentage of 
cells in each phase was determined by flow cytometry after propidium iodide staining.  Decrease 
in the proportion of cells in the G1 phase of the cell cycle and increase in the S and G2-M phase 
was observed. 
Figure 6Histogram of cell cycle distribution in control cells and cells treated with L-
asparaginase.Values were expressed as mean ± SD. (*P<0.05) represents the statistical 
significance between control and L-asparaginase treated cells by student’s t-test. 
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Figure 7Effect of purified L-asparaginase on haemolysis of human erythrocytes. T1 to T6: Cells 
treated with different concentrations of L-asparaginase (10, 20, 40, 80, 160 and 320 
µg/ml).Values were expressed as mean ± SD. (*P< 0.05, **P< 0.01, ***P< 0.001) represents the 
statistical significance between control and L-asparaginase treated cells by student’s t-test. 
